Dongman (Shenzhen) Artificial Intelligence Co., Ltd. (referred to as Dongman Medical) initially focused on the high‑end cancer medical market, and has expanded its reach to inclusive healthcare built on its self‑developed large medical model. Upholding the values of “Pragmatism, Innovation and Courage to Take Responsibility”, the company commits to empowering medical diagnosis and health management with AI technology. Its vision is to become a world‑leading provider of medical‑AI solutions, advance the intelligent transformation of the healthcare industry, and ultimately realize the goal of “intelligent and inclusive healthcare”. At present, Dongman Medical has set up subsidiaries in Hong Kong, Singapore, Shenzhen, Qingdao, Shanghai, Xiong’an, Zhejiang, Jiangsu and other regions. It is cooperating with renowned universities and tech enterprises to build a key laboratory for AI‑driven healthcare, and carries out joint research on clinical tumor auxiliary decision‑making systems with oncology departments of top‑tier Grade‑A tertiary hospitals in China. Meanwhile, the company is in discussions with multiple listed enterprises at home and abroad for international market deployment to build global‑oriented healthcare scenarios.